MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Botulinum toxin: Clinical applications: spasticity"

  • 2022 International Congress

    Treating Upper Limb Spasticity With OnabotulinumtoxinA: Subgroup Analysis of US Practice Patterns From the ASPIRE Study

    G. Francisco, W. Feng, M. Munin, K. Ngo, M. Schwartz, M. Sadeghi, A. Zuzek, A. Esquenazi (Houston, USA)

    Objective: To examine onabotulinumtoxinA (onabotA) treatment utilization patterns in the United States (US) for pronated forearm and intrinsic plus hand postures in patients with upper…
  • MDS Virtual Congress 2021

    OnabotulinumtoxinA treatment in patients with upper limb and lower limb spasticity from the ASPIRE study

    G. Bavikatte, G. Francisco, A. Esquenazi, M. Dimyan, K. Ngo, M. Schwartz, A. Zuzek, W. Jost (Liverpool, United Kingdom)

    Objective: Examine onabotulinumtoxinA utilization in patients with upper limb (UL) and lower limb (LL) spasticity from the Adult Spasticity International Registry (ASPIRE) study to gain…
  • MDS Virtual Congress 2021

    Assessing effectiveness of abobotulinumtoxinA injections for adult lower limb spasticity in routine clinical practice: The ongoing AboLiSh study

    A. Esquenazi, R. Zorowitz, S. Ashford, F. Calvi-Gries, P. Maisonobe, S. Page, J. Jacinto (Elkins Park, USA)

    Objective: The aim of this ongoing observational study is to systematically assess goal attainment over 16 months in patients treated with ≥1 abobotulinumtoxinA (aboBoNT-A) injection(s)…
  • MDS Virtual Congress 2021

    Absence of neutralizing antibody formation during incobotulinumtoxinA treatment of spasticity in botulinum toxin-naïve children with cerebral palsy: pooled analysis of Phase 3 studies

    H. Chambers, P. Kaňovský, A. Schroeder, E. Dabrowski, T. Geister, A. Hanschmann, I. Pulte, M. Althaus, M. Banach, D. Gaebler-Spira, F. Heinen (San Diego, USA)

    Objective: To investigate neutralizing antibody (NAb) formation in three large Phase 3 studies with incobotulinumtoxinA, a botulinum neurotoxin type A (BoNT-A) with no complexing proteins,…
  • MDS Virtual Congress 2021

    Efficacy and safety of incobotulinumtoxinA for upper- or combined upper- and lower-limb spasticity in children/adolescents with cerebral palsy: the XARA study

    E. Dabrowski, H. Chambers, D. Gaebler-Spira, M. Banach, P. Kaňovský, A. Hanschmann, M. Althaus, T. Geister, F. Heinen (Royal Oak, USA)

    Objective: To assess the efficacy/safety of incobotulinumtoxinA for upper- and combined upper-/lower-limb spasticity in ambulant and non-ambulant children/adolescents with cerebral palsy (CP). Background: Spastic CP…
  • MDS Virtual Congress 2021

    A phase IV, randomized, double-blind cross-over study comparing the clinical safety, efficacy and duration of abobotulinumtoxinA with onabotulinumtoxinA in adults with upper-limb spasticity: The DIRECTION study

    A. Esquenazi, Z. Ayyoub, M. Verduzco-Gutierrez, P. Maisonobe, J. Otto, A. Patel (Elkins Park, USA)

    Objective: To evaluate the safety and efficacy of abobotulinumtoxinA in comparison to onabotulinumtoxinA when used at optimized doses in approved muscles common to both products’…
  • MDS Virtual Congress 2021

    Improvement of spasticity-related pain with incobotulinumtoxinA treatment in children/adolescents with cerebral palsy: pooled analysis of Phase 3 studies

    F. Heinen, P. Kaňovský, A. Schroeder, H. Chambers, E. Dabrowski, T. Geister, A. Hanschmann, I. Pulte, M. Althaus, M. Banach, D. Gaebler-Spira (Munich, Germany)

    Objective: To assess the effect of incobotulinumtoxinA on spasticity-related pain (SRP) using pooled data from three large Phase 3 pediatric studies. Background: In children/adolescents with…
  • MDS Virtual Congress 2021

    Pooled efficacy and safety analysis of incobotulinumtoxinA for upper- and lower-limb spasticity in children with severe cerebral palsy (GMFCS levels IV–V)

    P. Kaňovský, D. Gaebler-Spira, A. Schroeder, H. Chambers, E. Dabrowski, T. Geister, A. Hanschmann, I. Pulte, M. Althaus, M. Banach, F. Heinen (Olomouc, Czech Republic)

    Objective: To assess the efficacy and safety of incobotulinumtoxinA for lower-limb (LL) and upper-limb (UL) spasticity in children and adolescents with cerebral palsy (CP) and…
  • MDS Virtual Congress 2021

    COMPARISON OF ELECTROPHYSIOLOGIC AND ULTRASOUND GUIDANCE FOR ONABOTULINUM TOXIN-A INJECTIONS IN FOCAL UPPER EXTREMITY SPASTICITY AND DYSTONIA

    C. Lungu, A. Nmashie, MC. George, T. Wu, S. Shin, B. Karp, E. Considine, W. Tse, S. Frucht, C. Wu, V. Koo, G. Norato, K. Alter, M. Hallet, DM. Simpson ()

    Objective: To investigate two targeting techniques for onabotulinum toxin-A (BoNT) injection for the treatment of focal hand dystonia and upper limb spasticity: guidance with electrical…
  • MDS Virtual Congress 2021

    Neutralizing Antibody Conversion With OnabotulinumtoxinA From Global Studies Across Multiple Indications With A Focus On Movement Disorders: A Meta-Analysis

    J. Jankovic, J. Carruthers, M. Naumann, T. Boodhoo, S. Gupta, M. Attar, R. Singh, I. Yushmanova, J. Soliman, MF. Brin, J. Shen (Houston, USA)

    Objective: A meta-analysis of clinical trial data across 10 indications for onabotulinumtoxinA was performed to assess incidence of neutralizing antibody (nAb) formation with a focus…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 7
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Patients with Essential Tremor Live Longer than their Relatives
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Life expectancy with and without Parkinson’s disease in the general population
  • The hardest symptoms that bother patients with Parkinson's disease
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley